bioMérieux stock

BIM · Euronext Paris · EUR

Compare bioMérieux
€91.30Change from previous close: +0.16%Absolute change: +€0.15

Close · November 20, 2026

Price history

−13.62% over the period

1 year: from €105.70 (November 20, 2025) to €91.30 (November 20, 2026), −13.62%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€91.30
October 30, 2026€90.50
September 30, 2026€77.75
August 31, 2026€75.05
July 31, 2026€69.10
June 30, 2026€68.70
May 29, 2026€74.35
April 30, 2026€71.70
March 31, 2026€91.80
February 27, 2026€100.00
January 30, 2026€97.80
December 31, 2025€110.30
November 28, 2025€107.90
November 20, 2025€105.70

At a glance

  • The company

    Develops and sells in vitro diagnostic solutions for infectious diseases, including microbiology, PCR and mass spectrometry systems

  • Latest results

    Quarter to June 30, 2026 · EPS €1.91

TickerLandia's take on bioMérieux

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€65.60
52-wk high€116.10

−21.36% from the 52-week high

Analysts · 13 analysts

Average target€89.04−2.48% vs. price

Buy 2 · Hold 10 · Sell 1 · Hold

TickerLandia Fingerprint: bioMérieux

Compared with similar companies: very high financial strength.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

bioMérieux is priced as in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), bioMérieux's P/E today is 27.3, in line with the median of its last 10 fiscal years (32.1; between 24.7 and 37.2 from 2016 to 2025). bioMérieux's P/E (trailing 12 months): 23.4, −31% against the median of a group of 11 similar companies (33.9).

P/E compared with its history

Compared with 11 similar companies

bioMérieux's metrics compared with similar companies
MetricbioMérieuxPosition in the groupBand
P/E (trailing 12 months)23.4Low
Forward P/E19.5Middle
Operating margin16.0%Middle
ROE11.2%Middle
Debt/equity0.10Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: bioMérieux. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€1.96B

Latest quarter · Q2 2026

Net income

€226.1M

Latest quarter · Q2 2026

Quarterly net margin

11.5%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€10.75B
P/E
23.4
EPS
€3.90
Volume
112.79K
Daily trading
€13.92M
Dividend yield
1.07%
Last ex-dividend on June 9, 2026

How bioMérieux is changing

All results
  • Revenue grew 5.5% a year on average over the last 5 years

  • Free cash flow equal to 74% of net income

  • Revenue has grown for 9 fiscal years in a row

Returns

bioMérieux returns with dividends

€1,000 invested in bioMérieux 5 years ago, on November 22, 2021, would be worth €789 today with dividends reinvested: −21.08% in total, −4.63% per year. On price alone it would be €752 (−24.76%).

PeriodbioMérieuxCAC 40€1,000 becomes
1 month+4.70%+1.14%€1,047
6 months+25.67%−2.34%€1,257
Year to date−17.23%−2.72%€828
1 year−12.44%−0.67%€876
3 years−1.85%+9.39%€982
5 years−21.08%+11.58%€789
10 years+122.66%+75.02%€2,227

Over the last 6 months it has done better than 65% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. CAC 40: price only. Calculate your investment

The chart in detail

bioMérieux: technical analysis

bioMérieux shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 36.3% below its all-time closing high (€143.40, October 12, 2020).

Trend
No clear trend
RSI (14 sessions)
57
Between 30 and 70
vs 200-session average
+13.84%

Support and resistance

Price areas where bioMérieux has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€102.20+11.94%2 touches, last on February 27, 2026
  2. Last price€91.30
  3. Support€87.80−3.83%2 touches, last on April 13, 2026
  4. Support€74.60−18.29%5 touches, last on October 2, 2026
  5. Support€71.63−21.55%2 touches, last on August 19, 2026

Volatility and risk

Over the last year it has moved little with the CAC 40.

Beta (1 year) vs CAC 40
0.26
Volatility (60 sessions, annualised)
24.2%
Largest fall in the last year
−41.99%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

bioMérieux: seasonality

Average monthly price change over 23 years

+2.6%Jan−0.3%Feb+0.9%Mar−0.5%Apr+3.7%May−0.5%Jun+3.4%Jul+0.3%Aug−1.0%Sep+0.9%Oct+0.7%Nov+2.8%Dec

Over the last 23 years, the strongest month for bioMérieux has been May: +3.72% on average, positive in 15 years out of 22. The weakest has been September: −1.01% on average, positive in 12 years out of 23. November, the current month, has been positive in 11 years out of 22 (+0.70% on average).

Show chart data
MonthAverageMedianPositive years
January+2.63%+2.67%14 of 22
February−0.31%−0.74%10 of 22
March+0.87%+0.01%11 of 22
April−0.53%−1.98%7 of 22
May+3.72%+3.14%15 of 22
June−0.53%+0.33%11 of 22
July+3.42%+3.59%16 of 22
August+0.28%−0.15%11 of 23
September−1.01%+0.47%12 of 23
October+0.86%−1.44%11 of 23
November+0.70%−0.06%11 of 22
December+2.79%+2.20%16 of 22

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

bioMérieux and its competitors

Many clinicians and laboratories know bioMérieux through VITEK 2, BIOFIRE and VIDAS, the systems used to identify bacteria, test their resistance to antibiotics and detect infections. The range also includes BACT/ALERT blood culture instruments, the VITEK MS mass spectrometry platform and API identification strips. Beyond these instruments, the group supplies culture media, PCR tests for viral respiratory infections and detection kits for the food industry, along with lab consultancy and training. It sells in France, across Europe, Africa, the Middle East, the Americas and Asia Pacific.

Headquarters
Marcy-l'Étoile, France
Employees
14,562
Founded
1963
Chief executive
Pierre Boulud
bioMérieux and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
bioMérieuxBIM$11.82B16.0%23.4+25.67%
QiagenQIA$10.23B26.7%28.5+50.69%
Eurofins ScientificERF$16.03B14.1%29.6+37.31%
DiaSorinDIA$4.21B22.3%28.6+14.88%
Lonza GroupLONN$54.2B23.5%43.2+32.22%
DiagnostykaDIA$1.27B14.9%20.2−6.62%

Same industry or related industries, similar size. Compare bioMérieux with its competitors · Full profile